Inhibition of betulinic acid to growth and angiogenesis of human colorectal cancer cell in nude mice

Chinese-German Journal of Clinical Oncology

Volumn 9, Issue 3, 2010, Pages 153-157

  Ren, Wenjuan ^a   Qin, Liyuan ^a   Xu, Ying ^a   Cheng, Niuliang ^a  

^a SHANXI MEDICAL UNIVERSITY   (China)

Author keywords

Betulinic acid; Colorectal cancer; Nude mice; Vascular endothelial growth factor (VEGF)

Indexed keywords

BETULIC ACID; MESSENGER RNA; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; COLORECTAL CANCER; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR NECROSIS; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 77956211783     PISSN: 16101979     EISSN: 16139089     Source Type: Journal    
DOI: 10.1007/s10330-010-0002-1     Document Type: Article

References (15)

1. Ni JT, Yi YF, Shi HP. Expressions of Maspin, p53 and Skp2 in colorectal tumors and their clinicopathological significance. Chin J cancer Res (Chinese), 2009, 21: 147-153.
2. Zhang L, Yu D, Hu M, et al. Wild-Type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Res, 2000, 60: 3655-3661.
3. Fan F, Wey JS, McCarty MF, et al. Expression and function of vascu- lar endothelial growth factor receptor-1 on human cancer cells. Oncogene, 2005, 24: 2647-2653.
4. Ishibashi H, Nakagawa K, Onimaru M, et al. Sp1 decoy transfected to carcinoma cell suppresses the expression of vascular endothelial growth factor, transforming growthfactor β, and tissue factor and also cell growth and invasion activities. Cancer Res, 2000, 60: 6531-6536.
5. Kessler JH, Mullauer FB, Medema JP, et al. Broad in vitro efficacy of plant-derived betulinic acid against cell lines derived from the most prevalent human cancer types. Cancer Lett, 2007, 251: 132-145.
6. Fulda S, Jeremias I, Steiner HH, et al. Betulinic acid: A new cytotoxic agent against malignant brain-tumor cells. Int J Cancer, 1999, 82: 435-441.
7. Chintharlapalli S, Papineni S, Ramaiah SK, et al. Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors. Cancer Res, 2007, 67: 2816-2823.
8. Selzer E, Pimentel E, Wacheck V, et al. Effects of betulinic acid alone and in combination with irradiation in human melanoma cells. J Invest Dermatol, 2000, 114: 935-940.
9. Folkman J. Tumor angiogenesis: Therapeutic implications. N EngL J Med, 1971, 285: 1182-1186.
10. Bando H. Vascular endothelial growth factor and bevacitumab in breast cancer. Breast Cancer, 2007, 14: 163-173.
11. Curry JM, Eubank TD, Roberts RD, et al. M-CSF signals through the MAPK/ERK pathway via Sp1 to induce VEGF production and induces angiogenesis in vivo. Plos One, 2008, 3: 3405.
12. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol, 2002, 20: 4368-4380.
13. Luo R, Kong WJ, Wang YJ. Elevated expressions of survivin and VEGF proteins are strong independent predictors of survival in squamous carcinoma of larynx. Chinese-German J Clin Oncol, 2008, 7: 661-665.
14. Fulda S. Betulinic acid for cancer treatment and prevention. Int J Mol Sci, 2008, 9: 1096-1107.
15. Mukherjee R, Jaggi M, Rajendran P, et al. Betulinic acid and its derivatives as anti-angiogenic agents. Bioorg Med Chem Lett, 2004, 14: 2181-2184.